Contract Pharma5d
Merck’s WELIREG Accepted for Priority Review by FDA for Pheochromocytoma and Paraganglioma
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Cure Today4d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma. The U.S. Food and Drug Administration (FDA) has ...
Targeted Oncology5d
FDA Grants Belzutifan Priority Review For Advanced Pheochromocytoma and Paraganglioma
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...
Nature6d
The FGF family: biology, pathophysiology and therapy
Fibroblast growth factors (FGFs) signal through FGF receptor tyrosine kinases to regulate a wide range of biological processes during development and adulthood. FGF receptors (FGFRs) are involved ...
BMJ4d
Acute pulmonary embolism 1: pathophysiology, clinical presentation, and diagnosis
Dr Martin Riedel, Deutsches Herzzentrum und I. Medizinische Klinik, Technische Universität München, Lazarettstr. 36, D-80636 München, Germanym.riedel{at}dhm.mhn.de If you wish to reuse any or all of ...
The Australian Financial Review2d
Perpetual Limited
Portfolio management, financial planning, trustee, responsible entity and compliance services, executor services, investment administration and custody services.